Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 15/20 | 0.39 |
| ▸ | NTRK3 | Q16288 | 7/20 | 0.39 |
| ▸ | JAK2 | O60674 | 5/20 | 0.36 |
| ▸ | NTRK2 | Q16620 | 5/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16946747 | 1.00 | NTRK1 (0.39) | NTRK1NTRK3JAK2NTRK2ALK | |
| SCHEMBL16947090 | 0.87 | NTRK1 (0.41) | NTRK1NTRK3JAK2NTRK2 | |
| SCHEMBL21076797 | 0.87 | NTRK1 (0.41) | NTRK1NTRK3JAK2NTRK2 | |
| SCHEMBL16946750 | 0.80 | NTRK1 (0.37) | NTRK1NTRK3JAK2NTRK2 | |
| SCHEMBL18352377 | 0.76 | TRPA1 (0.35) | JAK2ALK | |
| SCHEMBL16946791 | 0.76 | TRPA1 (0.35) | JAK2ALK | |
| SCHEMBL16947001 | 0.76 | IRAK4 (0.42) | NTRK1NTRK3JAK2NTRK2 | |
| SCHEMBL22454712 | 0.75 | NTRK1 (0.56) | NTRK1NTRK3NTRK2 | |
| SCHEMBL21510192 | 0.75 | JAK2 (0.39) | NTRK1NTRK3JAK2NTRK2ALK | |
| SCHEMBL24159345 | 0.74 | NTRK1 (0.57) | NTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216465-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TURNING POINT THERAPEUTICS INC (US) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216465-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | NTRK1 1072/4885NTRK3 1453/4885JAK2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.